Table 5.
Sensitivity analyses of cancers attributable to infectious agents in Nigeria from GLOBOCAN 2012 database.
| Infectious agent | Cancer site | ICD-O3 code | No. of cancer cases | ASR | PAF % | Cancer cases attributable to infections | ASR |
|---|---|---|---|---|---|---|---|
| Female | |||||||
| HPV | Cervix | C53 | 14,089 | 29.0 | 100 | 14,089 | 29.0 |
| Vulva | C51 | NA | NA | NA | NA | NA | |
| Vagina | C52 | NA | NA | NA | NA | NA | |
| Anus | C21 | NA | NA | NA | NA | NA | |
| Oropharynx | C01–C02; C09–C10 | NA | NA | NA | NA | NA | |
| HBV/HCV | Liver | C22 | 4,172 | 8.1 | 92 | 3,838 | 7.5 |
| EBV | Nasopharynx | C11 | 406 | 0.6 | 100 | 406 | 0.6 |
| HL | C81 | 345 | 0.5 | 80 | 276 | 0.4 | |
| EBV/HIV | NHL | C82–C85; C96 | 1,778 | 2.8 | 100 | 1,778 | 2.8 |
| HIV/HHV8 | KS | C46 | 635 | 0.8 | 100 | 635 | 0.8 |
| H. pylori | Stomach | C16 | 1,014 | 2.0 | 74 | 750 | 1.5 |
| Schistosoma | Bladder | C67 | 523 | 0.7 | 57 | 298 | 0.4 |
| Total (% of female cancers) | 22,962 (35.5%) | 44.5 | 22,084 (34.1%) | 43.0 | |||
| Male | |||||||
| HPV | Penis | C60 | NA | NA | NA | NA | NA |
| Anus | C21 | NA | NA | NA | NA | NA | |
| Oropharynx | C01–C02; C09–C10 | NA | NA | NA | NA | NA | |
| HBV/HCV | Liver | C22 | 7,875 | 15.0 | 92 | 7,245 | 13.8 |
| EBV | Nasopharynx | C11 | 656 | 1.1 | 100 | 656 | 1.1 |
| HL | C81 | 559 | 0.8 | 80 | 447 | 0.6 | |
| EBV/HIV | NHL | C82–C85; C96 | 2,328 | 3.7 | 100 | 2,328 | 3.7 |
| HIV/HHV8 | KS | C46 | 812 | 1.3 | 100 | 812 | 1.3 |
| H. pylori | Stomach | C16 | 875 | 2.0 | 74 | 648 | 1.5 |
| Schistosoma | Bladder | C67 | 574 | 1.3 | 57 | 327 | 0.7 |
| Total (% of male cancers) | 13,679 (36.6%) | 25.2 | 12,463 (33.4%) | 22.7 | |||
| Total (% of cancers in both sexes) | 36,641 (35.9%) | 50.0 | 34,547 (33.8%) | 47.4 | |||
NA means data not available.